Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Rapid Impact Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Metabolism Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Spotlight on Genomic Analysis of Rare and Understudied Cancers
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Research
Molecular Cancer Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Rapid Impact Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Metabolism Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Spotlight on Genomic Analysis of Rare and Understudied Cancers
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Poster Presentations - Proffered Abstracts

Abstract A26: Precise characterization and comparison of KRAS proteoforms by top-down mass spectrometry

Caroline J. DeHart, Lissa C. Anderson, Lauren M. Adams, Luca Fornelli, Christopher L. Hendrickson and Neil L. Kelleher
Caroline J. DeHart
1Northwestern University, Evanston, IL,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lissa C. Anderson
2National High Magnetic Field Laboratory, Tallahassee, FL.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lauren M. Adams
1Northwestern University, Evanston, IL,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Luca Fornelli
1Northwestern University, Evanston, IL,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christopher L. Hendrickson
2National High Magnetic Field Laboratory, Tallahassee, FL.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Neil L. Kelleher
1Northwestern University, Evanston, IL,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1557-3125.RAS18-A26 Published May 2020
  • Article
  • Info & Metrics
Loading
Abstracts: AACR Special Conference on Targeting RAS-Driven Cancers; December 9-12, 2018; San Diego, CA

Abstract

The two KRAS isoforms, 4A and 4B, exhibit high sequence identity, differing mainly in their C-terminal “hypervariable regions”, which bear post-translational modifications (PTMs) governing their association with the plasma membrane and downstream signaling effectors. Moreover, the KRAS gene bears three “mutation hotspot” residues (Gly12, Gly13, and Gln61) represented in a high percentage of human cancers. The similarity between KRAS isoforms, in addition to HRAS and NRAS, renders linking KRAS mutations and PTMs significantly challenging by standard proteomic methods based on digestion of proteins into short peptides. However, intact modified protein forms, or proteoforms, of KRAS4A and KRAS4B can be identified and characterized by “top-down” (TD) proteomic methods, elucidating crosstalk between N-terminal mutations and C-terminal PTMs with precise molecular detail. Previously, we employed the TD approach as part of a novel workflow to precisely characterize KRAS4B proteoforms isolated from colorectal cancer cell lines and primary tumor samples by immunoprecipitation (IP) and subsequent analysis on a benchtop Orbitrap mass spectrometer (1). Here, we modified our IP-TD protocol to include KRAS4A, then applied our workflow to the characterization, quantification, and direct comparison of KRAS4A and KRAS4B proteoforms within the context of multiple cancer cell lines. We hypothesized that we would be able to identify distinct proteoform populations for each KRAS isoform, which could then be compared both within and between different contexts. We have thus far identified nine novel proteoforms of KRAS4A, which not only exhibits differential PTM to KRAS4B, but varies widely in both abundance and PTM profile across all cell lines evaluated. We have also applied IP-TD to the analysis of endogenous KRAS4A and KRAS4B proteoforms using a more powerful 21 Tesla FT-ICR mass spectrometer at the National High Magnetic Field Laboratory. The high mass resolving power, mass measurement accuracy, and spectral acquisition rate achieved at high field combined with use of efficient dissociation methods and an external fragment ion accumulator to improve signal-to-noise ratios of MS/MS spectra produced unparalleled results with respect to degree of KRAS proteoform characterization. We were able to identify up to ten new KRAS proteoforms per context, several of which appear to be mutation- or context-specific. These latest advances have broadened our understanding of KRAS biology and provided new insights into the potential roles of KRAS4A and KRAS4B proteoforms in colorectal and other cancers.

Reference

1. Ntai I, Fornelli L, DeHart CJ, Hutton JE, Doubleday PF, LeDuc RD, van Nispen AJ, Fellers RT, Whiteley G, Boja ES, Rodriguez H, Kelleher NL. Precise characterization of KRAS4b proteoforms in human colorectal cells and tumors reveals mutation/modification crosstalk. Proc Natl Acad Sci U S A 2018 Apr 17;115(16):4140-5.

Citation Format: Caroline J. DeHart, Lissa C. Anderson, Lauren M. Adams, Luca Fornelli, Christopher L. Hendrickson, Neil L. Kelleher. Precise characterization and comparison of KRAS proteoforms by top-down mass spectrometry [abstract]. In: Proceedings of the AACR Special Conference on Targeting RAS-Driven Cancers; 2018 Dec 9-12; San Diego, CA. Philadelphia (PA): AACR; Mol Cancer Res 2020;18(5_Suppl):Abstract nr A26.

  • ©2020 American Association for Cancer Research.
Previous
Back to top
Molecular Cancer Research: 18 (5 Supplement)
May 2020
Volume 18, Issue 5 Supplement
  • Table of Contents

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Abstract A26: Precise characterization and comparison of KRAS proteoforms by top-down mass spectrometry
(Your Name) has forwarded a page to you from Molecular Cancer Research
(Your Name) thought you would be interested in this article in Molecular Cancer Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Abstract A26: Precise characterization and comparison of KRAS proteoforms by top-down mass spectrometry
Caroline J. DeHart, Lissa C. Anderson, Lauren M. Adams, Luca Fornelli, Christopher L. Hendrickson and Neil L. Kelleher
Mol Cancer Res May 1 2020 (18) (5 Supplement) A26; DOI: 10.1158/1557-3125.RAS18-A26

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Abstract A26: Precise characterization and comparison of KRAS proteoforms by top-down mass spectrometry
Caroline J. DeHart, Lissa C. Anderson, Lauren M. Adams, Luca Fornelli, Christopher L. Hendrickson and Neil L. Kelleher
Mol Cancer Res May 1 2020 (18) (5 Supplement) A26; DOI: 10.1158/1557-3125.RAS18-A26
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Poster Presentations - Proffered Abstracts

  • Abstract B32: A specialized post-transcriptional program in chemoresistant, quiescent cancer cells
  • Abstract B28: Estrogen receptor alpha (ERa) promotes protein synthesis by fine-tuning the expression of the eukaryotic translation initiation factor 3 subunit f (eIF3f)
  • Abstract A29: Targeted disruption of PI3K/Akt/mTOR signaling pathway induces cell cycle arrest, apoptosis, autophagy, and inhibits inflammation, invasion, and angiogenesis of OSCC cells
Show more Poster Presentations - Proffered Abstracts

Proffered Abstracts

  • Abstract B32: A specialized post-transcriptional program in chemoresistant, quiescent cancer cells
  • Abstract B28: Estrogen receptor alpha (ERa) promotes protein synthesis by fine-tuning the expression of the eukaryotic translation initiation factor 3 subunit f (eIF3f)
  • Abstract A29: Targeted disruption of PI3K/Akt/mTOR signaling pathway induces cell cycle arrest, apoptosis, autophagy, and inhibits inflammation, invasion, and angiogenesis of OSCC cells
Show more Proffered Abstracts
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Rapid Impact Archive
  • Meeting Abstracts

Information for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCR

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Research
eISSN: 1557-3125
ISSN: 1541-7786

Advertisement